Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas

Pituitary

Volumn 15, Issue 2, 2012, Pages 222-226

  Gabalec, Filip ^a   Beranek, Martin ^a   Netuka, David ^a   Masopust, Vaclav ^a   Nahlovsky, Jiri ^a   Cesak, Tomas ^a   Marek, Josef ^a   Cap, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Clinically non functioning adenomas; Dopamine D2 receptor; Immunohistochemistry; Pituitary adenomas; Real Time PCR

Indexed keywords

DOPAMINE 2 RECEPTOR; ESTROGEN; GONADOTROPIN; HYDROCORTISONE; HYPOPHYSIS HORMONE; MESSENGER RNA; TESTOSTERONE; THYROXINE;

ACTH SECRETING ADENOMA; ADOLESCENT; ADULT; AGED; ARTICLE; DIFFERENTIAL DIAGNOSIS; ENDOCRINE SURGERY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; HYPOGONADISM; HYPOPITUITARISM; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONFUNCTIONING PITUITARY ADENOMA; NULL CELL ADENOMA; PLURIHORMONAL ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CLASSIFICATION; TUMOR VOLUME;

ADENOMA; HUMANS; IMMUNOHISTOCHEMISTRY; PITUITARY NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DOPAMINE D2;

EID: 84861457024     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0316-1     Document Type: Article

References (18)

1. Jaffe CA (2006) Clinically non-functioning pituitary adenoma. Pituitary 9(4):317-321. doi:10.1007/s11102-006-0412-9 (Pubitemid 44823899)
2. Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, Teramoto A (2008) Pathology of the human pituitary adenomas. Histochem Cell Biol 130(3):495-507. doi:10.1007/s00418-008-0472-1
3. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol 156(2):203-216. doi:10.1530/eje.1.02326 (Pubitemid 46554515)
4. Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23(5):625-638. doi: 10.1016/j.beem.2009.05.005
5. Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: A study of 142 patients. Eur J Endocrinol 163(2):193-200. doi:10.1530/EJE-10-0255
6. Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008) Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15(4):905-915. doi: 10.1677/ERC-08-0181
7. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P Jr., de Carvalho DP, Kineman RD, Gadelha MR (2009) Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 94(6):1931-1937. doi:10.1210/jc.2008-1826
8. Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89(4):1674-1683 (Pubitemid 38507920)
9. Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider G II, Segev Y, Ouaknine G, Stern N (2005) Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf) 63(1):39-44. doi:10.1111/j.1365-2265.2005. 02295.x (Pubitemid 40966400)
10. Cap J,Cerman J,Nemecek S,Marekova M,Hana V, FrysakZ (2003) The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas. J Clin Neurosci 10(4):444-448. doi:S096758680 3000729
11. O'Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, Ruszniewski P, Barlier A (2006) The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol 155(6):849-857. doi:10.1530/eje.1.02307 (Pubitemid 46040624)
12. Al-Shraim M, Asa SL (2006) The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol 111(1):1-7. doi:10.1007/s00401-005-1093-6 (Pubitemid 43013820)
13. LambertsSW,MacleodRM(1990) Regulation of prolactin secretion at the level of the lactotroph. Physiol Rev 70(2):279-318 (Pubitemid 20140183)
14. Bevan JS, Burke CW (1986) Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf) 25(5):561-572 (Pubitemid 16008966)
15. Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G (1998) Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 83(1):248-252 (Pubitemid 28498345)
16. Nishioka H, Tamura K, Iida H, Kutsukake M, Endo A, Ikeda Y, Haraoka J (2011) Co-expression of somatostatin receptor subtypes and estrogen receptor-Alpha mRNAs by non-functioning pituitary adenomas in young patients. Mol Cell Endocrinol 331(1):73-78. doi:10.1016/j.mce.2010.08.011
17. Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M, Weindl A, Stalla GK (1998) Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 83(4):1368-1375 (Pubitemid 28496421)
18. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y (2009) Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 56(4):579-584. doi:JST.JSTAGE/endocrj/K08E-186